Skip to main content
GSK unveils data on study for myeloma drug belantamab mafodotin

GlaxoSmithKline's experimental treatment of belantamab mafodotin exhibited a meaningful response among patients with multiple myeloma who have undergone three prior treatment options. GSK also announced plans to seek regulatory approval for the drug later this year.

Full Story: